News Lilly and Boehringer biosimilar undercuts Lantus by 15% Sanofi under pressure following long-awaited biosimilar launch.
News Five UK pharma companies "named and shamed" by watchdog Companies' actions discredited the industry, says PMCPA.
News Lilly/Boehringer's long-acting diabetes pill approved in US Long-release pill is eighth drug to come from diabetes partnership.
News Diabetes drug Jardiance gains landmark cardiovascular approv... Lilly and Boehringer Ingelheim will now be able to promote their drug Jardiance in the US as a way for diabetes patients to reduce their risk of having a heart attack or stroke.
News BeyondSpring plans three-pronged attack on cancer The CEO of BeyondSpring said the company hopes to make its name with a new lung cancer drug and an innovative R&D strategy.
News Boehringer and Sarah Cannon team for immune-oncology venture Partnership will seek to develop two immune checkpoint inhibitor candidates.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
